To include your compound in the COVID-19 Resource Center, submit it here.

Daclizumab meets RRMS endpoint

Biogen Idec Inc. (NASDAQ:BIIB) and partner Abbott Laboratories (NYSE:ABT) said once-monthly subcutaneous daclizumab met the primary endpoint of annualized relapse

Read the full 209 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE